Brokerage firm Canaccord Genuity is taking a new leap as it upgrades its ratings on Biomed Realty Trust. This is a move that will determine the course and direction of the company.
As the new upgrade brings new opportunities, more awareness is also being felt and seen by the company in terms of growth and stability. Based on the latest info, Canaccord Genuity raises the price target to $23.00 per share from a prior target of $21.00. The shares have been rated as Buy. Previously, the market analyst had a Hold score on the counter. The assessment by Canaccord Genuity was issued on Sept. 23, 2015. Canaccord Genuity is a full service global banking and finance services company established in the 1950s.
Biomed Realty Trust (NYSE:BMR): The mean short term price target for Biomed Realty Trust (NYSE:BMR) has been set at $22.43 per share. The higher price target estimate is at $24 and the lower price target estimate is expected at $20 according to 7 Analyst, as stated in a post by News Watch International.
The stock price is anticipated to differ grounded on the approximation which is proposed by the standard deviation value of $1.48. The business shares have dropped 4.42 percent in the past 52 Weeks as well. On Jan. 27, 2015, the stocks itemized a one year high of $25.11 and a one year low was seen on Sept. 1, 2015 at $17.94. The 50-day moving average is $19.79 and the 200 day moving average is recorded at $20.62. S&P 500 has rallied 1.82% during the last 52-weeks, as further reported by Benzinga.
Looking at the shares of Biomed Realty Trust (NYSE:BMR), it ended Tuesday session in red amid unpredictable transaction. The shares closed down 0.56 points or 2.84 percent at $19.18 with 1,496,812 shares getting traded, as further noted by News Watch International.
BioMed Realty Trust, Inc. functions as a real estate investment trust (REIT). It possesses, obtains, advances, improves, lets and manages laboratory and office space for the life science industry.
